Comparative Pharmacology
Head-to-head clinical analysis: ORBACTIV versus SATRIC.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ORBACTIV versus SATRIC.
ORBACTIV vs SATRIC
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Oritavancin is a lipoglycopeptide antibiotic that inhibits bacterial cell wall synthesis by binding to the D-alanyl-D-alanine terminus of the peptidoglycan precursor, disrupting transglycosylation and transpeptidation. It also disrupts bacterial membrane integrity and causes depolarization, leading to cell death.
SATRIC is a combination of sulfathiazole, sulfacetamide, and sulfabenzamide, which are sulfonamide antibiotics. They competitively inhibit dihydropteroate synthase, blocking folate synthesis in susceptible bacteria.
1200 mg IV once daily for 3 days
No standard dosing information available for SATRIC.
None Documented
None Documented
Terminal elimination half-life is approximately 15.1 hours in healthy adults; in patients with renal impairment, half-life is prolonged (up to 28 hours in severe renal impairment).
3-5 hours in healthy adults; prolonged to 6-8 hours in renal impairment (CrCl < 30 mL/min)
Primarily renal excretion as unchanged drug (approximately 33% of administered dose) and via biliary/fecal elimination (~50% recovered in feces as parent drug and metabolites).
Renal: 70% unchanged; fecal: 20%; biliary: 10%
Category C
Category C
Antibiotic
Antiprotozoal, Antibiotic